

PAR/CS/NSE/2025-26/45

Date: 10/02/2026

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Subject: Outcome of the Board Meeting held on Tuesday, 10th day of February, 2026 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015

Ref.: Symbol- PAR, ISIN: INE04LG01015

Dear Sir/Madam,

The meeting of Board of Directors of the Company held on Tuesday, **10th day of February, 2026** at **3:30 PM** through Video Conferencing ("VC") mode , transacted the following businesses:

| Item No. | Outcomes |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | <p>After the recommendation of Audit Committee, the Board of Directors considered, approved and took on record the Unaudited Standalone Financial Results of the Company for quarter and nine month ended on 31st December, 2025 along with Limited Review Report given by CA Miral Mehta, Partner of Sarupria Somani & Associates, Chartered Accountants having valid Peer Review Certificate, Statutory Auditor of the Company. The Board authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbbhai Savani, CEO & Director (DIN: 00198203) to sign the approved financial results with notes. The financial results were duly reviewed by Audit Committee at its meeting. Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Certificate of correctness was placed before the Board Meeting as attached herewith in the annexure.</p> <p>(Limited Review Report with statements of financial are attached as an Annexure)</p> |
| 2. | <p>The Board considered and approved the drafts of advertisements to be published in newspapers regarding Unaudited Standalone Financial Results of the Company for the quarter and nine month ended on 31st December, 2025. The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay or as available.</p> |



| | |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3. | The Board took note of Investor grievances report for the quarter ended 31 st December, 2025 and reviewed the SCORES platform of SEBI to solve the investor compliant till date. |
| 4. | The Board took note and review the Corporate Governance Report of the Company for the quarter ended 31 st December, 2025 |
| 5. | The Board of Directors evaluated the performance of present Independent directors of the Company find proper and qualified. |
| 6. | The Board took note that the company has paid earned leave to the employees of the Company total of Rs . 11.49 Lakh for the calendar year 2025 start from January 2025 to December 2025. |
| 7. | The Board reviewed the policy on Related Party Transactions and approved the amendments of policy as per regulatory updates. |
| 8. | There were no other material items to be discussed and taken for proposal. |

Further, with reference to our intimation dated 29th December, 2025 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will be opened after 48 hours of declaration of the attached financial result for Designated persons, Designated employees and their Immediate relatives.

The Board Meeting was commenced at 3:30 PM and concluded at 5:14 PM.

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,

For PAR DRUGS AND CHEMICALS LIMITED

(Sanket B. Trivedi)

Company Secretary & Compliance Officer



Annexure:

1. Limited Review Report on standalone un-audited Quarterly and nine month ended 31st December, 2025
2. Standalone Un-Audited Financial Results for the Quarter and nine month ended 31st December, 2025 with notes
3. Certificate of Correctness of financial Statement



Sarupria Somani & Associates
Chartered Accountants

Partner : CA Miral Bipinbhai Mehta
B.Com, FCA

CA Miral B. Mehta
602, Victoria Corporate,
Opp. Gulista Ground, Sony Sh
Room Lane, Vadodariya Park,
Bhavnagar. Gujarat-364001
Mobile : 9909366366
Email : somanibvn@gmail.com

Limited Review Report on standalone un-audited Quarterly financial results for the quarter and nine month ended 31st December, 2025 of Par Drugs and Chemicals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,
The Board of Directors
Par Drugs and Chemicals Limited

We have reviewed the accompanying statement of unaudited financial results of **Par Drugs and Chemicals Limited** having its registered office at 815, Nilamber Triumph, Gotri Vasna Road, Vadodara, Gujarat-390007 for the quarter and nine month ended 31st December, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

SARUPRIA SOMANI & ASSOCIATES

(Firm Regn No. – 010674C)

CHARTERED ACCOUNTANTS


MIRAL MEHTA (Partner)

M.No.145361

Bhavnagar, 10th February, 2026

UDIN - 26145361XNNSF7314

Branches

Udaipur • Ahmedabad • Akola • Mumbai • Delhi • Singruli • Jaipur • Gandhinaga

Rudrapur • Indore • Pune • Kolkata • Ghaziabad • Raipur • Shimla • Chandigarh

PAR DRUGS AND CHEMICALS LIMITED
(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India
Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com
Standalone Audited Financial Results for the Quarter and Nine Month Ended 31st December, 2025
Statement Of Profit & Loss

(Rs. in Lakhs)

| | Particulars | Quarter Ended | | | Year to Date | | Year Ended |
|-------|------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|
| | | 31-12-2025 | 30-09-2025 | 31-12-2024 | 31-12-2025 | 31-12-2024 | 31-03-2025 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| I | Revenue from operations | 2,933.95 | 2,865.89 | 2,138.11 | 8,404.48 | 7,864.36 | 10,097.35 |
| II | Other income | 132.55 | 48.01 | 27.18 | 364.23 | 136.14 | 215.03 |
| III | Total Revenue (I + II) | 3,066.50 | 2,913.90 | 2,165.29 | 8,768.71 | 8,000.50 | 10,312.38 |
| IV | Expenses: | | | | | | |
| | Cost of materials consumed | 1,211.91 | 1,054.23 | 888.62 | 3,382.46 | 2,897.39 | 3,940.86 |
| | Purchases of Stock-in-Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Changes in inventories of finished goods, Stock-in-Trade and work-in-progress | 27.48 | 18.13 | -7.77 | 62.84 | -62.09 | -127.83 |
| | Employee benefits expense | 141.01 | 135.49 | 132.08 | 418.47 | 394.18 | 585.18 |
| | Finance costs | 1.48 | 5.49 | 1.41 | 8.59 | 6.34 | 8.21 |
| | Depreciation and amortization expense | 93.13 | 94.11 | 91.44 | 277.58 | 272.63 | 364.66 |
| | Other expenses | 947.29 | 1,051.43 | 982.27 | 2,971.77 | 2,927.63 | 3,749.01 |
| | Total expenses (IV) | 2,422.30 | 2,358.88 | 2,088.05 | 7,121.71 | 6,436.08 | 8,520.09 |
| V | Profit / (loss) before exceptional items and tax (III-IV) | 644.20 | 555.02 | 77.24 | 1,647.00 | 1,564.42 | 1,792.29 |
| VI | Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| VII | Profit / (loss) before tax (V - VI) | 644.20 | 555.02 | 77.24 | 1,647.00 | 1,564.42 | 1,792.29 |
| VIII | Tax expense: | | | | | | |
| | (1) Current tax | 164.48 | 142.06 | 19.44 | 421.51 | 393.73 | 452.50 |
| | (2) Deferred tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 |
| IX | Profit / (Loss) for the period from continuing operations (VII-VIII) | 479.72 | 412.96 | 57.80 | 1,225.49 | 1,170.69 | 1,335.79 |
| X | Profit / (loss) from discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XI | Tax expense of discontinued operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XII | Profit / (loss) from Discontinued operations (after tax) (X-XI) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIII | Profit / (Loss) for the period (IX + XII) | 479.72 | 412.96 | 57.80 | 1,225.49 | 1,170.69 | 1,335.79 |
| XIV | Other Comprehensive Income | | | | | | |
| | A (i) items that will not be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (ii) income tax relating to items that will not be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | B (i) items that will be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (ii) income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XV | Total Comprehensive Income for the period (comprising profit / (loss) and other comprehensive income for the period) (XIII + XIV) | 479.72 | 412.96 | 57.80 | 1,225.49 | 1,170.69 | 1,335.79 |
| XVI | Paid up Equity share capital (Face value of Rs. 10 each) | 1,230.46 | 1,230.46 | 1,230.46 | 1,230.46 | 1,230.46 | 1,230.46 |
| XVII | Reserves & Surplus excluding revaluation reserve | 9,882.75 | 9,412.80 | 8,501.74 | 9,882.75 | 8,501.74 | 8,667.03 |
| XVIII | Earnings per equity share (for discontinued operation) | | | | | | |
| | (1) Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (2) Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIV | Earnings per equity share (for discontinued & continuing operation) (EPS for 3 and 9 months ended periods are not annualised) | | | | | | |
| | (1) Basic | 3.90 | 3.36 | 0.47 | 9.96 | 9.51 | 10.86 |
| | (2) Diluted | 3.90 | 3.36 | 0.47 | 9.96 | 9.51 | 10.86 |


For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani
Director & CEO
(DIN - 00198203)



For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Faigun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)



PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)


Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

NOTES:

1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time.
2. The above quarterly and nine month ended financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th February, 2026.
3. The Statutory auditors of the company have carried out Limited Review of the above quarterly & nine month ended financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS.
5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures.
6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.
7. The Company does not have any subsidiary, associates or joint venture as on 31st December, 2025; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.



PAR DRUGS AND CHEMICALS LIMITED

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara (Gujarat)

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com


8. The above unaudited financial results of the Company are available on the Company's website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company's shares are listed.

9. The Status of investors complaints are as follows:

| | | |
|----------------------------------------------------|---|---|
| I. Pending at the beginning of the quarter | - | 0 |
| II. Received during the quarter | - | 3 |
| III. Disposed-off during the quarter | - | 3 |
| IV. Remaining unresolved at the end of the quarter | - | 0 |

For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)



For and on behalf of Board of Directors
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani
(Director & CEO)
(DIN - 00198203)



Vadodara, 10th February, 2026

To,
The Board of Directors
Par Drugs And Chemicals Limited

CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for the quarter and nine month ended on December 31st, 2025 placed before the meeting do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

For Par Drugs And Chemicals Limited

Date: 10/02/2026


Place: Bhavnagar



(Mr. Jignesh V. Savani)
Chief Executive Officer



For Par Drugs And Chemicals Limited



(Mr. Chintan P. Chauhan)
Chief Financial Officer

